230 related articles for article (PubMed ID: 20218923)
1. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.
Durando P; Icardi G; Ansaldi F
Expert Opin Biol Ther; 2010 Apr; 10(4):639-51. PubMed ID: 20218923
[TBL] [Abstract][Full Text] [Related]
2. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
O'Hagan DT
Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
[TBL] [Abstract][Full Text] [Related]
3. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
[TBL] [Abstract][Full Text] [Related]
4. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates.
Ansaldi F; Zancolli M; Durando P; Montomoli E; Sticchi L; Del Giudice G; Icardi G
Vaccine; 2010 Jun; 28(25):4123-9. PubMed ID: 20433807
[TBL] [Abstract][Full Text] [Related]
5. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
6. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
Ansaldi F; Bacilieri S; Durando P; Sticchi L; Valle L; Montomoli E; Icardi G; Gasparini R; Crovari P
Vaccine; 2008 Mar; 26(12):1525-9. PubMed ID: 18294741
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence.
Vesikari T; Karvonen A; Tilman S; Borkowski A; Montomoli E; Banzhoff A; Clemens R
Pediatrics; 2010 Oct; 126(4):e762-70. PubMed ID: 20819892
[TBL] [Abstract][Full Text] [Related]
8. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria) in adult and elderly subjects.
Gasparini R; Schioppa F; Lattanzi M; Barone M; Casula D; Pellegrini M; Veitch K; Gaitatzis N
Int J Clin Pract; 2010 Mar; 64(4):432-8. PubMed ID: 20039974
[TBL] [Abstract][Full Text] [Related]
9. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
[TBL] [Abstract][Full Text] [Related]
10. The virosomal adjuvanted influenza vaccine.
Calcagnile S; Zuccotti GV
Expert Opin Biol Ther; 2010 Feb; 10(2):191-200. PubMed ID: 20088714
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.
Atmar RL; Keitel WA; Patel SM; Katz JM; She D; El Sahly H; Pompey J; Cate TR; Couch RB
Clin Infect Dis; 2006 Nov; 43(9):1135-42. PubMed ID: 17029131
[TBL] [Abstract][Full Text] [Related]
12. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations.
Puig Barberà J; González Vidal D
Expert Rev Vaccines; 2007 Oct; 6(5):659-65. PubMed ID: 17931147
[TBL] [Abstract][Full Text] [Related]
13. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
Puig-Barberà J; Natividad-Sancho A; Calabuig-Pérez J; Lluch-Rodrigo JA; Pastor-Villalba E; Martínez-Úbeda S; Pérez-Vilar S; Díez-Domingo J
Vaccine; 2013 Aug; 31(37):3995-4002. PubMed ID: 23731629
[TBL] [Abstract][Full Text] [Related]
14. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
15. Adjuvanted seasonal influenza vaccines and perpetual viral metamorphosis: the importance of cross-protection.
Ansaldi F; Canepa P; Parodi V; Bacilieri S; Orsi A; Compagnino F; Icardi G; Durando P
Vaccine; 2009 May; 27(25-26):3345-8. PubMed ID: 19200846
[TBL] [Abstract][Full Text] [Related]
16. Open, randomized study to compare the immunogenicity and reactogenicity of an influenza split vaccine with an MF59-adjuvanted subunit vaccine and a virosome-based subunit vaccine in elderly.
Ruf BR; Colberg K; Frick M; Preusche A
Infection; 2004 Aug; 32(4):191-8. PubMed ID: 15293073
[TBL] [Abstract][Full Text] [Related]
17. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.
Pellegrini M; Nicolay U; Lindert K; Groth N; Della Cioppa G
Vaccine; 2009 Nov; 27(49):6959-65. PubMed ID: 19751689
[TBL] [Abstract][Full Text] [Related]
18. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
[TBL] [Abstract][Full Text] [Related]
19. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis.
Banzhoff A; Nacci P; Podda A
Gerontology; 2003; 49(3):177-84. PubMed ID: 12679609
[TBL] [Abstract][Full Text] [Related]
20. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A
Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
